

Figure S1. The knockdown efficiency of two siRNA targeting C9orf9.




Figure S2. Cell cycle analysis of C9orf9 overexpression (A) and knockdown (B) in LoVo and SW480 cells.




Figure S3. Wound scratch assay in C9orf9 overexpression (A) and knockdown (B) LoVo cells. ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.




Figure S4. Wound scratch assay in C9orf9 overexpression (A) and knockdown (B) SW480 cells. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.




Figure S5. C9orf9 did not response to TGF-β (A) or IGF (B)-induced EMT in SW480 cells. ns not significant, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

Table S1. Amplification and sequencing primers for C9orf9.

Gene	Exon	5' Primer name	Sequence	3' Primer name	Sequence	Seq Primer	Sequence	PCR Length
C9orf9	E2	>C9orf9_E2_F	AAGGCGCTCCAGTG AGAGGG	>C9orf9_E2_R	CTTTTGTGAGAGGGG ACTGG	>C9orf9_E2_F	CCCTGACAGTCC TTCCCTCC	359bp
	E3	>C9orf9_E3_F	GTAGGGTGGGAGGG AGTAGG	>C9orf9_E3_R	GAGCAGCATCAGAGG GACTT	>C9orf9_E3_S F	TGGACATTGCA CCATAAGC	330bp
	E4	>C9orf9_E4_F	GGAGCATGGGTTCAC CTG	>C9orf9_E4_S R	GTTTGAGGCTGGCTTT TGTG	>C9orf9_E4_S R3	TGTCTACACTTG TGTTTAGT	309bp
	E5	>C9orf9_E5_F	AAATGTGTCCCTGGC TTCTG	>C9orf9_E5_R	ACTGCCCAGTGTCTT TGAT	>C9orf9_E5_S R	GTCTTAGGGGA GATGTAGGT	222bp

Table S2. Q-PCR primers used in this study.

Gene	Product length	Forward primer	Reverse primer
CDH1	119 bp	CGAGAGCTACACGTTACGG	GGGTGTCGAGGGAAAAATAGG
GAPDH	86bp	TGGAAATCCCATCACCATCT	TGGACTCCACGACGTACTCA
C9orf9	111bp	GAGAACGCCACGACAAGA	CAGGAACATGAGCAGAACCC
CDH2	123bp	TGCGGTACAGTGTAAGTGGG	GAAACCGGGCTATCTGCTCG
VIM	98bp	AGTCCACTGAGTACCGGAGAC	CATTTACGCATCTGGCGTTC
TIMP1	96bp	ACCACCTTATACCAGCGTTATGA	GGTGTAGACGAACCGGATGTC
VEGFA	75bp	AGGGCAGAATCATCACGAAGT	AGGGTCTCGATTGGATGGCA
NDUFB1	61bp	GTCCCTATGGGATTGTGATTGG	CAGTTAGCCGTTCACTACTCTT
NDUFA3	95bp	GGGGCCTCGCTGTAATTCTG	GACGGGCACTGGGTAGTTG